Mazdutide vs retatrutide: what the trial data actually shows

Last updated 2026-07-25

What is mazdutide and how is it different from retatrutide?

Mazdutide is a synthetic peptide developed by Innovent Biologics, a China-based drugmaker, in partnership with Eli Lilly for some markets. It's a dual agonist, meaning it activates two receptors: GLP-1 and glucagon. Retatrutide goes one step further. It's a triple agonist, hitting GLP-1, GIP, and glucagon receptors all at once ^[1]. That third receptor, GIP, is the same one tirzepatide (Mounjaro, Zepbound) uses alongside GLP-1. Retatrutide adds glucagon receptor activity on top of that combination, which is the mechanistic case for why its trial weight loss numbers run higher than tirzepatide's and, so far, higher than what's been published for mazdutide. Both drugs work on the same broad idea: incretin and glucagon signaling drives weight loss and glucose control. But they are not the same molecule, they are not made by the same primary sponsor for US purposes, and they are not at the same stage of regulatory review in the United States. Retatrutide is Lilly's molecule (development code LY3437943) and has a fairly mature US trial record. Mazdutide's clinical program has run largely in China, with Innovent as the lead sponsor, and its footprint in US-registered trials and US regulatory filings is much thinner by comparison. If you're trying to decide which one has "better data," the honest answer is that they're not on equal footing in terms of what's publicly verifiable in US-facing databases. That asymmetry matters more than people expect when comparing the two.

How does the trial weight loss data compare?

Retatrutide's headline number comes from a phase 2 obesity trial published in the New England Journal of Medicine: a mean weight reduction of 24.2 percent at the 12 mg dose at 48 weeks, versus 2.1 percent for placebo, with weekly subcutaneous dosing ^[1]. That trial is registered on ClinicalTrials.gov as NCT04881760 ^[2], and the record spells out the dose arms and route. Retatrutide didn't stop there. It has since moved into later-phase registered trials, including NCT05929066 ^[3] and NCT05882045 ^[4], which list enrollment criteria, comparators, and endpoints for the next stage of testing. There's also a type 2 diabetes trial program running in parallel to the obesity work ^[2], so the evidence base isn't limited to one population. Mazdutide's public numbers are less consolidated in the sources a US reader can easily verify. Without a peer-reviewed US-indexed trial of comparable size and follow-up length to point to here, the fair comparison is: retatrutide has a large, well-documented, NEJM-published phase 2 dataset with a specific number attached to a specific dose and timepoint. Anyone telling you a precise, sourced mazdutide weight-loss percentage should be able to point you to the specific trial registry or journal publication it came from, the same way retatrutide's 24.2 percent figure traces straight back to NEJM ^[1] and ClinicalTrials.gov ^[2]. That's not a knock on mazdutide as a molecule. It's a statement about what's independently verifiable right now for a US audience. | Feature | Retatrutide | Mazdutide |

Is mazdutide FDA-approved? Is retatrutide FDA-approved?

No, and no. A Drugs@FDA query for the generic name retatrutide returns no approved product ^[5]. Mazdutide has no FDA approval either. Neither drug has cleared an NDA (New Drug Application) in the United States, which means neither can legally be introduced into interstate commerce as a marketed drug under 21 U.S.C. 355 ^[7]. This is worth sitting with for a second, because vendor sites often imply otherwise through omission. "In late-stage trials" and "FDA-approved" are not the same status, and neither compound has reached the second one. If you see either name being sold online as a finished product, that sale is happening outside the regulatory system that would normally vouch for its purity, dose accuracy, and safety. For context on what lawful incretin options do exist: semaglutide is approved and marketed as Ozempic and Wegovy, and tirzepatide as Mounjaro and Zepbound ^[5]. Orforglipron, an oral GLP-1 agonist, was approved as Foundayo under NDA 220934 in six strengths from 0.8 mg to 17.2 mg ^[8], giving patients an approved oral option where before there was only injectable therapy. None of those approvals extend to retatrutide or mazdutide.

Can you legally buy or compound either drug in the US?

No, for both, and the legal reasoning is the same regardless of which molecule you're asking about. Section 503A of the Food, Drug, and Cosmetic Act lets a compounding pharmacy make a drug from a bulk substance only through a specific cascade: the substance has to comply with a USP or NF monograph if one exists, or, absent a monograph, be a component of an FDA-approved drug, or, only if neither of those applies, appear on the 503A Bulks List ^[9]. Retatrutide satisfies none of the three conditions. Mazdutide doesn't either. Neither has a USP monograph, neither is a component of an approved drug, and neither appears on the Bulks List. The complete 503A Bulks List contains exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide ^[6]. No peptide is on that list, full stop. The separate 503B bulks list, which governs outsourcing facilities rather than compounding pharmacies, also excludes retatrutide ^[10], and mazdutide isn't on it either. There's a second, independent requirement that trips up gray-market material even if the ingredient cascade were somehow satisfied: 503A also requires every bulk drug substance to come from an establishment registered under FD&C Act section 510 and to be accompanied by a valid certificate of analysis ^[9]. Research-use-only material from an unregistered supplier fails this requirement regardless of anything else about the molecule. That's a second, independent way that vendor material fails, on top of the ingredient-cascade problem. So for both mazdutide and retatrutide, there is currently no lawful path for a US pharmacy to compound either one for patient use. That's true no matter how the vendor labels the vial.

Why do gray-market vendors sell these as 'research use only'?

Because that label is meant to dodge drug-marketing rules, and it doesn't actually work if the surrounding marketing tells a different story. FDA has been explicit about this. "Intended use" for a substance is established by labeling claims, advertising matter, or oral or written statements made by the seller, not by a disclaimer stuck on the bottle ^[11]. In a March 2026 warning letter to a peptide vendor, FDA wrote that despite a research-use-only disclaimer, evidence from the company's website established that its products were intended to be drugs for human use. That letter specifically named retatrutide as one of the products marketed on the site ^[12]. If a site's actual copy talks about fat loss, appetite suppression, or dosing for people, FDA can and does treat that as drug marketing regardless of the small print, and there's no reason to think mazdutide sold the same way would be treated differently. This matters for buyers, more than sellers. A disclaimer doesn't change what's in the vial, doesn't guarantee sterility, and doesn't create a legal purchase where none exists. It's a liability shield for the seller, not a safety guarantee for you.

Has either drug been nominated for the 503A Bulks List?

Retatrutide has never been nominated for the 503A Bulks List. FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 to consider seven peptides for possible inclusion: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax, and epitalon ^[13]. Retatrutide wasn't among them. Mazdutide wasn't either. Even if a substance does get a favorable advisory committee vote, that doesn't create a compounding pathway by itself. FDA advisory committee recommendations are non-binding, and actually adding something to the Bulks List requires full notice-and-comment rulemaking ^[13], which takes time measured in years, not months. FDA maintains a public roster of nominated substances and where they sit in that process ^[14], and neither retatrutide nor mazdutide appears on it at all, meaning neither has even entered the queue. So even in the best-case, fastest-moving scenario where a peptide clears every hurdle, retatrutide and mazdutide are not in that pipeline right now. Anyone telling you compounded retatrutide or mazdutide is "about to become legal" is speculating well past what the public record supports.

What does the dosing data show for each drug?

For retatrutide, the phase 2 obesity trial tested weekly subcutaneous injections across several dose arms, with the 12 mg arm producing the 24.2 percent mean weight reduction at 48 weeks reported in NEJM ^[1]. The trial registry NCT04881760 lists the specific dose arms and route studied ^[2], and later trials (NCT05929066 ^[3], NCT05882045 ^[4]) list further enrollment criteria and dosing comparators for ongoing testing. That's trial data, generated under a controlled protocol, with a placebo comparator, medical monitoring, and defined endpoints. It is not a home-use dosing schedule, and no clinician can lawfully prescribe retatrutide outside of a registered trial right now, because the drug has no FDA approval ^[5] and no compounding pathway ^{[6] [9]}. Mazdutide's published dosing details for a comparable US-relevant obesity endpoint are not consolidated in the same way in sources easily verified against a US registry. If you come across a specific mazdutide mg-per-week claim online, ask where it's from. A specific trial registry number or peer-reviewed publication is the bar. A vendor's dosing chart is not. If you want to understand what an actual retatrutide dosage chart looked like in trial conditions, or how a retatrutide dosage calculator might frame trial-reported dose ranges, those breakdowns exist for reference and context, not as a how-to for self-administration outside a trial.

What are the safety signals for mazdutide vs retatrutide?

Retatrutide's published phase 2 safety data comes from the same NEJM trial that reported the weight-loss numbers, and gastrointestinal effects (nausea, diarrhea, constipation) were the most commonly reported adverse events, consistent with the class-wide pattern seen in GLP-1 and dual/triple agonist trials ^[1]. A fuller breakdown of what was reported, and how the rates compared across dose arms, is worth reading directly on the retatrutide side effects page rather than taking a shortened summary at face value. Mazdutide's safety profile, as a GLP-1/glucagon dual agonist, would be expected on mechanistic grounds to show a broadly similar GI-adverse-event pattern, since GLP-1 receptor activation is the common driver of nausea and GI slowing across this drug class. But expected-on-mechanistic-grounds is not the same as verified-in-a-specific-published-trial, and this article isn't going to assign mazdutide a specific adverse event rate without a citation that actually supports one. What's true for both compounds without qualification: neither has the years of postmarket safety surveillance that approved drugs accumulate. Everything known about either drug right now comes from trial-phase data, which is real and useful but is not the same evidentiary weight as a drug that's been on pharmacy shelves for a decade.

If neither drug is legal to buy, what should someone do instead?

Talk to a prescriber about the incretin drugs that are actually approved. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved and have real postmarket safety data behind them ^[5]. Orforglipron (Foundayo, NDA 220934) adds an oral option in six strengths from 0.8 mg to 17.2 mg for patients who'd rather avoid injections ^[8]. None of these three matches retatrutide's 24.2 percent phase 2 weight-loss figure head to head yet, and that's a fair thing to be disappointed about if you were hoping for the biggest possible number. But they're legal, they're covered by insurance in many cases, and a doctor can actually monitor you on them, which is not something a gray-market vial from an unregistered supplier offers. NIDDK, the federal government's diabetes and digestive disease research institute, publishes plain guidance on evidence-based weight management approaches that's worth reading as a neutral baseline while you wait on any investigational drug . It's not exciting reading. It's also not selling you anything, which is more than can be said for most retatrutide or mazdutide marketing you'll run across. If you're weighing whether retatrutide might become available sooner through some other channel, the honest starting point is understanding why it can't currently be bought lawfully rather than looking for a workaround that doesn't exist under current law.

How does mazdutide vs retatrutide compare on trial phase and timeline?

Retatrutide has publicly registered phase 2 completed data (NEJM, 2023) ^[1] and is now running in later-phase trials with published registry entries (NCT05929066 ^[3], NCT05882045 ^[4]). That puts it further along a publicly documented US trial pathway than mazdutide appears to be, based on what's verifiable in US-facing registries and journals right now. This doesn't mean mazdutide's underlying program is behind everywhere; Innovent's China-based trials may be at a different stage than what shows up in US databases. But for a US reader trying to figure out which drug might reach the US market sooner, or which one has been tested longer under a design a US clinician would recognize, retatrutide currently has the more complete, more transparently sourced trail. Neither timeline should be read as a promise. Phase 2 success doesn't guarantee phase 3 success, and phase 3 success doesn't guarantee FDA approval on any particular date. Drug development fails at every stage, often for reasons unrelated to how good the early data looked.

Bottom line: mazdutide vs retatrutide, which has stronger evidence?

For a US-based reader, retatrutide currently has the stronger, more independently verifiable evidence trail: a published NEJM phase 2 trial with a specific number (24.2 percent weight loss at 12 mg, 48 weeks) ^[1], multiple ClinicalTrials.gov registrations ^{[2] [3] [4]}, and a triple-receptor mechanism that's mechanistically distinct from both semaglutide and tirzepatide ^[1]. Mazdutide is a legitimate dual-agonist candidate with its own development program, but its US-verifiable trial documentation is thinner, and this article isn't going to manufacture a false equivalence by inventing numbers for it that aren't backed by a citable US-indexed source. What's identical between the two: neither is FDA-approved ^[5], neither is on the 503A Bulks List ^[6], neither has a lawful US compounding pathway ^[9], and neither can be legally purchased for personal use no matter what a vendor's disclaimer says ^{[11] [12]}. If you want to read the fuller mechanistic and trial breakdown specific to retatrutide, the retatrutide peptide overview covers that in more depth, and the reconstitution and handling details researchers use in lab settings (never a home-use instruction) are covered separately in how to reconstitute retatrutide.

Frequently asked questions

Is mazdutide the same as retatrutide?

No. Mazdutide is a GLP-1/glucagon dual agonist from Innovent Biologics. Retatrutide is a GLP-1/GIP/glucagon triple agonist developed by Eli Lilly. They're different molecules with overlapping but not identical mechanisms, and neither is FDA-approved.

Which is more effective for weight loss, mazdutide or retatrutide?

Retatrutide's published phase 2 data shows 24.2% mean weight loss at the 12 mg dose over 48 weeks versus 2.1% for placebo (NEJM, 2023). Comparable, independently verifiable US-indexed trial data for mazdutide at that scale isn't readily available to cite directly.

Can I legally buy mazdutide or retatrutide in the US?

No. Neither drug is FDA-approved, and neither appears on the 503A Bulks List, so no US pharmacy can lawfully compound either one. A new drug can't legally enter interstate commerce without an approved application under 21 U.S.C. 355.

Why do vendors sell retatrutide as 'research use only'?

That label is meant to avoid drug-marketing rules, but FDA has said a disclaimer doesn't override actual marketing claims. In a March 2026 warning letter, FDA found a vendor's website established intended human use for retatrutide despite the disclaimer.

Is retatrutide on the FDA's list of substances allowed for compounding?

No. The 503A Bulks List has exactly six substances (Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, thymol iodide), none of them peptides, and retatrutide has never been nominated for the list at all.

What is the mechanism difference between mazdutide, retatrutide, semaglutide, and tirzepatide?

Semaglutide activates only the GLP-1 receptor. Tirzepatide activates GLP-1 and GIP. Mazdutide activates GLP-1 and glucagon. Retatrutide activates all three: GLP-1, GIP, and glucagon, making it the broadest-mechanism candidate of the group.

Has retatrutide been approved for type 2 diabetes?

No. Retatrutide has been studied in registered type 2 diabetes trials alongside its obesity program, but it has no FDA approval for any indication, diabetes included, as of the most recent Drugs@FDA database check.

What happened at the FDA's 2026 meeting on compounding peptides?

FDA's Pharmacy Compounding Advisory Committee met July 23-24, 2026 to review seven peptides (BPC-157, KPV, TB-500, MOTS-c, emideltide/DSIP, semax, epitalon) for possible Bulks List inclusion. Retatrutide and mazdutide were not part of that review.

Does a favorable FDA advisory committee vote make a peptide legal to compound?

No. Advisory committee recommendations are non-binding. Actually adding a substance to the 503A Bulks List requires full notice-and-comment rulemaking, a separate and much slower process, so a vote alone changes nothing legally.

What are the approved alternatives to mazdutide or retatrutide right now?

Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and orforglipron (Foundayo, an oral option approved in six strengths) are all FDA-approved incretin drugs available today through a prescriber, unlike mazdutide or retatrutide.

Is it safe to import mazdutide or retatrutide from overseas for personal use?

FDA publishes a specific personal importation policy that governs unapproved drugs ordered from abroad, and investigational compounds like these don't have a general exemption. Purity, dosing accuracy, and sterility also can't be verified outside a registered manufacturing and trial framework.

Does retatrutide have a USP monograph?

No. Retatrutide has no USP or NF monograph, isn't a component of any FDA-approved drug, and isn't on the 503A Bulks List, so it fails all three conditions of the legal cascade a compounder would need to satisfy under 21 U.S.C. 353a.

Sources

1. Jastreboff AM et al., New England Journal of Medicine, 2023: Retatrutide is a GLP-1/GIP/glucagon triple agonist; phase 2 trial showed 24.2% mean weight loss at 12 mg vs 2.1% placebo at 48 weeks, weekly subcutaneous dosing; GI adverse events were most common.
2. ClinicalTrials.gov NCT04881760: Registered phase 2 retatrutide obesity trial listing dose arms and route; also basis of parallel type 2 diabetes trial program.
3. ClinicalTrials.gov NCT05929066: Later-phase retatrutide trial registration listing enrollment criteria, comparators, and endpoints.
4. ClinicalTrials.gov NCT05882045: Second later-phase retatrutide trial registration confirming dosing and design under study.
5. Drugs@FDA, FDA-approved drug products database: A query for the generic name retatrutide returns no FDA-approved product.
6. 21 CFR 216.23, eCFR current through 2026-07-08: The complete 503A Bulks List contains exactly six substances, none a peptide, and retatrutide is not among them.
7. 21 U.S.C. 355: A new drug may not be introduced into interstate commerce without an approved application.
8. Drugs@FDA (NDA 220934): Orforglipron was approved as Foundayo under NDA 220934 in six strengths from 0.8 mg to 17.2 mg.
9. 21 U.S.C. 353a(b)(1)(A)(i): Section 503A permits compounding from a bulk substance only through the monograph/approved-drug-component/Bulks-List cascade, which retatrutide satisfies none of.
10. 21 CFR 216.24: The separate 503B bulks list for outsourcing facilities also does not include retatrutide.
11. 21 CFR 201.128: Intended use is grounded in labeling claims, advertising matter, or seller statements, not disclaimers.
12. Federal Register, Docket FDA-2025-N-6895, published 16 April 2026: FDA's Pharmacy Compounding Advisory Committee reviewed seven named peptides in July 2026, not including retatrutide, and advisory votes are non-binding pending rulemaking.
13. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA's public roster of nominated compounding substances does not include retatrutide.
14. NIDDK, Weight Management: NIDDK publishes federal guidance on evidence-based weight management as a neutral reference point.